The Promise of ALLO-501A in Relapsed/Refractory LBCL
Michael T. Tees, MD, discusses the data behind ALLO-501A, an allogeneic chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma.
Exploring The Donor-Derived CAR T-Cell Therapy, ALLO-501A
Michael T. Tees, MD, discusses chimeric antigen receptor T-cell therapies, including ALLO-501A, and its use for patients with relapsed or refractory large B-cell lymphoma.
Allogeneic CAR T-Cell Therapy Potentially Reduces GVHD Risk
Michael Tees, MD, discusses the preliminary safety outcomes observed for an allogeneic chimeric antigen receptor T-cell therapy for large B-cell lymphoma.